Eosinophilic colitis : an infrequent disease with difficult diagnose
© BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ..
Eosinophilic colitis (EC) is a rare entity. It is part of eosinophilic gastroenteritis, a rare inflammatory disorder characterised by eosinophilic infiltration of tissues that can affect any segment of the digestive tract. The diagnosis is established by the presence of an increased eosinophilic infiltrate in the colon wall in symptomatic patients. There is no characteristic clinical picture of EC. It can be associated with abdominal pain, changes in bowel movements, diarrhoea and rectal bleeding. Biopsies are mandatory if EC is suspected and despite visualising a normal mucosa. Although there are no protocol guidelines in this regard, steroid treatment is the first option in controlling the disease. Increasing the knowledge of clinicians and pathologists of this disorder and the recording its real incidence and population impact, could improve the understanding and treatment of the disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
BMJ case reports - 13(2020), 9 vom: 21. Sept. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Páramo-Zunzunegui, Javier [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
0K5C5T2QPG |
|---|
| Anmerkungen: |
Date Completed 22.02.2021 Date Revised 22.09.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/bcr-2020-235804 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315298014 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315298014 | ||
| 003 | DE-627 | ||
| 005 | 20231225154615.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/bcr-2020-235804 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1050.xml |
| 035 | |a (DE-627)NLM315298014 | ||
| 035 | |a (NLM)32958551 | ||
| 035 | |a (PII)e235804 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Páramo-Zunzunegui, Javier |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Eosinophilic colitis |b an infrequent disease with difficult diagnose |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.02.2021 | ||
| 500 | |a Date Revised 22.09.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a Eosinophilic colitis (EC) is a rare entity. It is part of eosinophilic gastroenteritis, a rare inflammatory disorder characterised by eosinophilic infiltration of tissues that can affect any segment of the digestive tract. The diagnosis is established by the presence of an increased eosinophilic infiltrate in the colon wall in symptomatic patients. There is no characteristic clinical picture of EC. It can be associated with abdominal pain, changes in bowel movements, diarrhoea and rectal bleeding. Biopsies are mandatory if EC is suspected and despite visualising a normal mucosa. Although there are no protocol guidelines in this regard, steroid treatment is the first option in controlling the disease. Increasing the knowledge of clinicians and pathologists of this disorder and the recording its real incidence and population impact, could improve the understanding and treatment of the disease | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a endoscopy | |
| 650 | 4 | |a general practice / family medicine | |
| 650 | 4 | |a general surgery | |
| 650 | 4 | |a inflammatory bowel disease | |
| 650 | 7 | |a Lansoprazole |2 NLM | |
| 650 | 7 | |a 0K5C5T2QPG |2 NLM | |
| 650 | 7 | |a Cromolyn Sodium |2 NLM | |
| 650 | 7 | |a Q2WXR1I0PK |2 NLM | |
| 650 | 7 | |a Prednisone |2 NLM | |
| 650 | 7 | |a VB0R961HZT |2 NLM | |
| 700 | 1 | |a Ortega-Fernandez, Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Benito-Barbero, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Rubio-López, Laura |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMJ case reports |d 2008 |g 13(2020), 9 vom: 21. Sept. |w (DE-627)NLM209291001 |x 1757-790X |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2020 |g number:9 |g day:21 |g month:09 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/bcr-2020-235804 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2020 |e 9 |b 21 |c 09 | ||